drugset / Trial / NCT00903786

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

NCT00903786

Phase 2 Completed 21 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to investigate the safety and tolerability of perampanel in long- term treatment in the patients with refractory partial epilepsy (uncontrolled with other anti-epileptic drugs) who completed Week 10 of Phase II Study E2007-J081-231 study.

Timeline

Start
2009-06-17
Primary completion
2016-08-08
Completion
2016-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 2 mg Oral
Subject Perampanel Small molecule 12 mg Oral

Indications